Is Myelodysplastic Syndrome (MDS) Cancer Curable?

Myelodysplastic syndrome is a blood cancer, and for a subset of patients it can be cured, but only through one treatment: allogeneic stem cell transplant. Cure rates with transplant range from roughly 30% to 70% depending on how advanced the disease is at the time of the procedure. The catch is that most people diagnosed with MDS are older adults who may not be healthy enough to tolerate a transplant, so the majority live with the disease as a chronic condition managed by therapies that control it without eliminating it. Understanding which category you fall into, and what the realistic options are, requires a closer look at how MDS behaves and how doctors decide on treatment.

Why MDS Is Considered a Cancer

For years, MDS occupied an awkward gray zone. Doctors sometimes described it to patients as a “pre-leukemia” or a “bone marrow failure disorder” rather than calling it cancer outright, partly because the language around it was genuinely unsettled. A paper in Leukemia Research examined this confusion directly, noting that MDS is a clonal neoplastic disorder of blood-forming tissue with a guarded prognosis, but physicians varied widely in whether they used the word “cancer” when talking to patients.¹ That ambiguity had real consequences: patients who were told they didn’t have cancer sometimes couldn’t access disability benefits, insurance coverage, or clinical trial enrollment.

Today, the medical consensus is clear. MDS is classified as a myeloid neoplasm, a category that includes other blood cancers like acute myeloid leukemia (AML). The bone marrow produces abnormal, immature blood cells that don’t function properly, leading to low blood counts and, in many patients, a risk of transformation into AML. A study tracking stem cell populations over time showed that MDS progression to AML originates at the stem cell level, confirming the fundamentally malignant nature of the disease.² So while MDS can behave more slowly than many cancers, it is a cancer by any meaningful definition.

How Often MDS Progresses to Leukemia

One of the first questions after a diagnosis is whether the disease will get worse, and if so, how fast. Not all MDS transforms into AML, and the pace varies enormously by risk group. A large study of nearly 2,000 patients who started in the low-risk category found that about two-thirds stayed low-risk throughout their disease course. Roughly 16% progressed to high-risk MDS without developing leukemia, about 6.5% moved from low-risk to high-risk and then to AML, and 9% jumped directly from low-risk MDS to AML.³

In practical terms, this means that a low-risk MDS diagnosis does not automatically mean leukemia is coming. Many patients live years or even a decade or more without their disease transforming. But monitoring matters, because the minority who do progress need treatment adjustments, and catching that shift early can change outcomes.

Risk Stratification and Why It Matters So Much

The treatment path for MDS depends heavily on where a patient falls on a risk scale. Doctors have traditionally used scoring systems that weigh factors like blood counts, the percentage of immature cells (blasts) in the bone marrow, and chromosome abnormalities. The newer Molecular International Prognostic Scoring System (IPSS-M) adds gene mutation data to the picture and does a measurably better job of predicting outcomes. A real-world validation study found that IPSS-M improved the ability to predict both overall survival and leukemia-free survival compared to the older IPSS-R system.⁴ A separate assessment confirmed the model’s improvement across overall survival, leukemia-free survival, and leukemic transformation.⁵

This scoring isn’t academic. A patient classified as very low-risk might be monitored with blood tests and managed with supportive care for years, while a patient classified as high-risk might be fast-tracked toward transplant. The specific gene mutations identified during testing also increasingly guide which drugs are chosen, making the molecular workup one of the most consequential steps in the entire treatment process.

Stem Cell Transplant as the Only Cure

Allogeneic hematopoietic stem cell transplant remains the sole treatment with genuine curative potential for MDS. The procedure replaces the patient’s diseased bone marrow with healthy donor cells. Depending on disease status at the time of transplant, between 30% and 70% of patients can be cured and survive long-term.⁶ For high-risk patients up to around age 70 without major other health problems, guidelines recommend transplant with curative intent, with cure rates for that group typically falling in the 30% to 50% range.⁷

Those numbers deserve honest context. A 30-50% cure rate means that more than half of high-risk patients who undergo transplant do not achieve a lasting cure, either because the disease returns or because the transplant itself causes fatal complications. But for patients facing a disease with a median survival of a few years or less under conventional treatment, those odds represent the best available chance.

Transplant in Older Patients

Because the median age at MDS diagnosis is in the early 70s, many patients are beyond the age range historically considered safe for transplant. Reduced-intensity conditioning regimens, which use lower doses of chemotherapy or radiation before the transplant, have made the procedure accessible to older adults. A study of 88 MDS patients aged 60 and older who received reduced-intensity transplants confirmed that the approach can produce long-term survival in this group.⁸ A larger European study of MDS patients aged 50 and above found no significant difference in survival, relapse, or treatment-related death between full-intensity and reduced-intensity conditioning, suggesting that the gentler regimens hold up without sacrificing effectiveness.⁹

Still, a decision analysis evaluating reduced-intensity transplant versus non-transplant therapies in older patients makes clear that transplant carries additional mortality risk that must be weighed against the potential for cure.¹⁰ This is why the decision is so individualized: fitness, comorbidities, disease risk category, and patient preference all factor in.

Graft-Versus-Host Disease and Other Transplant Risks

The transplanted donor cells have a beneficial side effect: they can attack lingering MDS cells in the body, a phenomenon called the graft-versus-tumor effect. But those same donor immune cells can also attack the patient’s healthy tissues, causing graft-versus-host disease (GVHD), which ranges from mild skin rashes to life-threatening organ damage.¹¹ A study measuring a composite outcome that factors in both GVHD and relapse found that three-year GVHD-free, relapse-free survival was about 35%.¹² That number captures the reality that surviving transplant without either relapse or serious ongoing complications is the higher bar to clear.

When a matched sibling donor is not available, haploidentical donors (family members who are only a half-match) are increasingly used as an alternative.¹³ Advances in post-transplant immune suppression have made these partially matched transplants viable, expanding the donor pool significantly.

Treatments That Control MDS Without Curing It

For patients who cannot undergo transplant, several therapies can slow disease progression and improve quality of life. The most widely used are hypomethylating agents, particularly azacitidine. A meta-analysis of multiple trials found that azacitidine improved overall survival and delayed transformation to AML.¹⁴ In a head-to-head comparison of the two main hypomethylating agents in lower-risk MDS, median overall survival was about 33 months.¹⁵ These drugs are not curative, but they can meaningfully extend life and keep the disease in check for months or years.

Newer combinations are pushing response rates higher. A phase 1b trial pairing venetoclax (a drug that targets a cancer survival protein) with azacitidine in previously untreated high-risk MDS patients found that about 80% achieved a marrow response, and median overall survival reached 26 months.¹⁶ In patients whose disease had already failed prior hypomethylating agent therapy, the same combination still produced responses in about half, though survival was shorter at a median of seven months.¹⁷ The gap between first-line and salvage results underscores how much harder MDS becomes to treat once it stops responding to initial therapy.

TP53 Mutations and the Hardest Cases

Among the most challenging MDS subgroups are patients with mutations in the TP53 gene, sometimes called the “guardian of the genome.” TP53-mutated MDS carries a particularly poor prognosis, and even transplant offers limited benefit. A study comparing outcomes found that patients with mutated TP53 had lower overall survival and higher relapse rates than those without, regardless of whether the mutation affected one or both copies of the gene.¹⁸ Among the TP53-mutated group, the two-year post-transplant survival was only around 35-45%, and pre-transplant chemotherapy did not improve those results compared to supportive care alone.

Experimental agents targeting TP53-mutated disease, including drugs like eprenetapopt and magrolimab, have been investigated but have not yet transformed outcomes for this group.¹⁹ This remains an active area of clinical trials, and researchers are also exploring immune-directed therapies including antibodies targeting TIM-3 and CD47.²⁰ For now, TP53-mutated MDS is the subtype where the honest answer to “is it curable?” is closest to “not yet, for most people.”

Managing Lower-Risk MDS

For patients whose disease is classified as lower-risk, the goal shifts from cure to managing symptoms and maintaining quality of life, sometimes for many years. The most common problem is anemia caused by the bone marrow’s failure to produce enough healthy red blood cells, leading to fatigue that can be debilitating. Many patients become dependent on regular blood transfusions.

Luspatercept, a drug that reduces abnormal signaling in the bone marrow, has shown strong results in this population. In a pivotal trial, 38% of patients treated with luspatercept achieved freedom from transfusions for at least eight weeks, compared to 13% on placebo.²¹ Longer follow-up from the COMMANDS trial, which compared luspatercept head-to-head against a standard erythropoiesis-stimulating agent, found that about 45% of luspatercept-treated patients achieved transfusion independence lasting a year or more, compared to roughly 28% on the comparator.²² Freedom from transfusions is not a cure, but for many patients it is the single biggest improvement in daily life.

Patients who do require ongoing transfusions face iron overload, a side effect that can damage the heart and liver over time. A randomized trial found that iron chelation therapy with deferasirox extended event-free survival by about a year compared to placebo.²³ A separate prospective analysis found that patients who received iron chelation had median survival of about five years from the onset of transfusion dependence, compared to about two years for those who did not.²⁴ The benefits of iron chelation tend to be underappreciated, in part because the treatment itself (daily oral medication or occasional infusions) can feel like a nuisance rather than active cancer care.

Knowing Whether Transplant Actually Worked

Even after a successful transplant, the question of cure lingers. Doctors increasingly rely on measurable residual disease (MRD) testing, which looks for tiny traces of MDS-related mutations in the blood or marrow using sensitive molecular techniques. A study of transplanted MDS patients found that those who tested MRD-positive had roughly eight times the risk of relapse compared to those who were consistently MRD-negative. MRD positivity was also independently linked to shorter overall survival.²⁵ Encouragingly, a group of patients who initially tested positive later converted to negative, and some of those went on to remain in remission. This kind of monitoring is becoming standard practice and helps doctors decide whether additional interventions, like donor immune cell infusions, are needed after transplant.

Therapy-Related MDS

Not all MDS arises on its own. Some patients develop it years after receiving chemotherapy or radiation for a different cancer, a form known as therapy-related MDS (t-MDS). A nationwide study confirmed that t-MDS carries a shorter median survival than the de novo form: about 16 months versus 31 months. Patients whose prior treatment involved chemotherapy had a significantly higher-risk profile than those treated with radiation alone, who more closely resembled the de novo MDS population.²⁶ This distinction matters because it affects both prognosis and treatment decisions. A breast cancer survivor who develops MDS a decade later faces a biologically different disease than someone diagnosed out of the blue.

Precursor States and Catching MDS Earlier

Before MDS fully develops, many people carry related conditions that may or may not progress. Clonal hematopoiesis of indeterminate potential (CHIP) refers to the presence of certain blood cell mutations without any symptoms or blood count abnormalities. Clonal cytopenia of undetermined significance (CCUS) adds low blood counts to the picture. Both carry distinct risks for eventually developing MDS or other myeloid cancers.²⁷

A risk-prediction model found that most people with CHIP or CCUS fall into a low-risk category with a very small ten-year probability of developing a myeloid cancer. But a small subset, those with multiple mutations, high mutation burden, certain high-risk gene mutations, or who are older, face substantially elevated risk. The model identified a high-risk group making up about 1% of cases in whom most cancer events were concentrated.²⁸ This kind of stratification may eventually allow intervention before MDS fully develops, though for now, most people with CHIP are simply monitored with periodic blood tests.

The Financial Side of MDS Treatment

Conversations about curability rarely address the financial toll, but it shapes real decisions. A study comparing patients who underwent transplant versus those managed with hypomethylating agents or supportive care found that transplant patients reported higher monthly out-of-pocket costs and financial hardship. Nearly half of transplant recipients reported financial hardship across multiple survey time points, though patients managed without transplant also faced substantial costs and strain.²⁹ The bone marrow microenvironment itself undergoes reprogramming during MDS, initially trying to suppress the abnormal cells but eventually shifting to support them.³⁰ Understanding this biology may eventually yield new therapeutic targets, but for now, the practical reality is that MDS treatment of any kind, whether curative or palliative, is expensive and prolonged, and financial toxicity deserves as much attention as the medical kind.